Business Context and Reporting Period
This Form 8-K was filed by RXi Pharmaceuticals Corporation (also referred to as Phio Pharmaceuticals Corp. in metadata) on March 7, 2013, reporting events occurring between March 1 and March 7, 2013. The filing details a strategic asset acquisition and a concurrent capital raising transaction.
Key Financial Metrics and Transaction Terms
The filing does not provide historical revenue, profit, cash flow, or margin data. Key financial terms of the reported transactions include:
- Asset Purchase Consideration: Issuance of 50,000,000 shares of common stock to OPKO Health, Inc., plus potential milestone payments of up to $50,000,000 per Qualified Drug and royalty payments (mid single-digit for ophthalmologic use; low single-digit for non-ophthalmologic use).
- Private Placement Proceeds: Sale of approximately 113 million shares at $0.145 per share for an aggregate price of approximately $16.4 million.
- Net Proceeds: Estimated net proceeds to the Company are approximately $16.0 million after commissions.
- Liquidity Condition: The asset purchase is contingent on the private placement raising at least $10 million in gross proceeds.
Material Changes and Transaction Structure
The Company entered into two material definitive agreements:
- Asset Purchase Agreement (March 1, 2013): Acquisition of substantially all RNAi-related assets (patents, licenses, data) from OPKO Health, Inc. The transaction closes concurrently with the private placement, subject to OPKO purchasing at least $5 million of the new stock.
- Securities Purchase Agreement (March 6, 2013): A private placement of common stock expected to close on March 12, 2013.
Both transactions involve significant dilution through the issuance of unregistered shares (50 million APA Shares and 113 million SPA Shares).
Guidance, Risks, and Contingencies
Registration Obligations and Penalties:
- The Company must file registration statements for the APA Shares within 45 days of resale registration and SPA Shares within 60 days of closing.
- Penalty for APA Shares: Failure to meet filing or effectiveness deadlines may result in a penalty of 2.0% of the total aggregate value of APA Shares, payable every 30 days.
- Penalty for SPA Shares: Failure to meet deadlines may result in a penalty of 1.0% of the holder's pro rata interest in the purchase price, payable every 30 days.
Contingencies: The asset purchase will not close unless the private placement raises at least $10 million. The filing includes a corporate presentation (Exhibit 99.1) which is not treated as "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the closing of the private placement on or before March 12, 2013, and confirmation that gross proceeds exceed $10 million.
- Confirm the issuance of 50 million APA Shares and 113 million SPA Shares and the resulting impact on share count and ownership dilution.
- Monitor the filing of registration statements for resale of the new shares to avoid the 1.0% and 2.0% penalty clauses.
- Review the full text of the Asset Purchase Agreement (to be filed in the next 10-Q) for specific definitions of "Qualified Drug" and "Net Sales."
- Assess the Company's cash position post-closing to determine runway for developing the acquired RNAi assets.